

DAFTAR PUSTAKA

- Aditia, A. (2021). *E-ISSN 2715-6885; p-ISSN 2714-9757* <http://jurnal.globalhealthsciencegroup.com/index.php/JPPP>. 3(3), 8.
- Agrawal, U., Raju, R., & Udwadia, Z. F. (2020). Favipiravir: A new and emerging antiviral option in COVID-19. *Medical Journal, Armed Forces India*, 76(4), 370–376. <https://doi.org/10.1016/j.mjafi.2020.08.004>
- Ahmed, M. H., & Hassan, A. (2021). Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): A Review. *Sn Comprehensive Clinical Medicine*, 1. <https://doi.org/10.1007/s42399-020-00610-8>
- Alfikrie, F., Akbar, A., & Anggreini, Y. D. (2021). *Pengetahuan dan Sikap Mahasiswa dalam Pencegahan COVID-19*. 3(1), 6.
- Alkautsar, A. (2021). Hubungan Penyakit Komorbid dengan Tingkat Keparahan Pasien COVID-19. *Jurnal Medika Hutama*, 3(01 Oktober), 1488–1494.
- Asmarawati, T., Rosyid, A. N., Suryantoro, S., Mahdi, B. A., Windradi, C., Wulaningrum, P. A., Arifianto, M. V., Bramantono, B., Triyono, E. A., Rusli, M., Rachman, B. E., Marfiani, E., Endraswari, P. D., Hadi, U., Kuntaman, K., & Nasronudin, N. (2021). The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. *F1000Research*. <https://doi.org/10.12688/f1000research.31645.2>
- Badan Pusat Statistik Provinsi Kalimantan Selatan*. (2022). Retrieved January 7, 2022, from <https://kalsel.bps.go.id/subject/6/tenaga-kerja.html>
- Burhan, E., Susanto, A. D., Nasution, S. A., Ginanjar, E., Pitoyo, W., Susilo, A., Firdaus, I., Santoso, A., Arifa, D., Arif, S. K., Syam, F., Rasmin, M., Rengganis, I., Sukrisman, L., Wiyono, W. H., Isbaniah, F., Elhidsi, M., Aniwidyaningih, W., Handayani, D., ... Sambo, M. (2020). *Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI)*. 149.
- Coleman, J. J., & Pontefract, S. K. (2016). Adverse drug reactions. *Clinical Medicine*, 16(5), 481–485. <https://doi.org/10.7861/clinmedicine.16-5-481>
- Coronavirus Disease 2019 (COVID-19) Treatment Guidelines*. (2021). 365.
- Crescioli, G., Brilli, V., Lanzi, C., Burgalassi, A., Ieri, A., Bonaiuti, R., Romano, E., Innocenti, R., Mannaioni, G., Vannacci, A., & Lombardi, N. (2021). Adverse drug reactions in SARS-CoV-2 hospitalised patients: A case-series

- with a focus on drug–drug interactions. *Internal and Emergency Medicine*, 16(3), 697–710. <https://doi.org/10.1007/s11739-020-02586-8>
- Damayanti, H., Sajinadiyasa, I. G. K., Risni, H. W., & Sauriasari, R. (2021). The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. *Kesmas: National Public Health Journal*, 16(4). <https://doi.org/10.21109/kesmas.v16i4.5433>
- Drew, C., & Adisasmita, A. C. (2021). *Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur, Maret-September 2020*. 3(3), 10.
- Falcão, F., Viegas, E., Carmo, I., Soares, J., Falcao, M., Solano, M., Cavaco, P., Mendes, D., Rijo, J., Povoa, P., Pais Martins, A., Carmo, E., Mansinho, K., Fonseca, C., Campos, L., Carvalho, A., Mirco, A., Farinha, H., Aldir, I., & Correia, J. (2021). A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: A preliminary report. *European Journal of Hospital Pharmacy*, 28(5), 248–253. <https://doi.org/10.1136/ejhp pharm-2020-002613>
- Fan, Q., Zhang, B., Ma, J., & Zhang, S. (2020). Safety profile of the antiviral drug remdesivir: An update. *Biomedicine & Pharmacotherapy*, 130, 110532. <https://doi.org/10.1016/j.biopharm.2020.110532>
- Farmakologi Obat Kortikosteroid. (2020, August 24). *Gudang Ilmu Farmasi*. <https://gudangilmu.farmasetika.com/farmakologi-obat-kortikosteroid/>
- FAVIKAL. (2021). Retrieved November 6, 2021, from <https://www.kalbemed.com/product/id/459>
- Hailu, A. D., & Mohammed, S. A. (2020). Adverse Drug Reaction Reporting in Ethiopia: Systematic Review. *BioMed Research International*, 2020, 1–12. <https://doi.org/10.1155/2020/8569314>
- Hardiana, M. E. (2011). *Jurusen Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam Universitas Islam Indonesia Yogyakarta Juli 2011*. 69.
- Hu, W., Chang, L., Yang, Y., Wang, X., Xie, Y., Shen, J., Tan, B., & Liu, J. (2021). Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. *Acta Pharmacologica Sinica*, 42(7), 1195–1200. <https://doi.org/10.1038/s41401-020-00537-9>
- Kaur, R. J., Charan, J., Dutta, S., Sharma, P., Bhardwaj, P., Sharma, P., Lugova, H., Krishnapillai, A., Islam, S., Haque, M., & Misra, S. (2020). Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. *Infection and Drug Resistance*, 13, 4427–4438. <https://doi.org/10.2147/IDR.S287934>

Keputusan_kepala_badan_pengawas_obat_dan_makanan_nomor_hk_02_02_1_2_03_20_134_tahun_2020. (2020). Retrieved February 2, 2022, from https://covid19.hukumonline.com/wpcontent/uploads/2020/04/keputusan_kepala_badan_pengawas_obat_dan_makanan_nomor_hk_02_02_1_2_03_20_134_tahun_2020.pdf

Lee, J. Y., Ang, A. S. Y., Mohd Ali, N., Ang, L. M., & Omar, A. (2021). Incidence of adverse reaction of drugs used in COVID-19 management: A retrospective, observational study. *Journal of Pharmaceutical Policy and Practice*, 14(1), 84. <https://doi.org/10.1186/s40545-021-00370-3>

Madelain, V., Nguyen, T. H. T., Olivo, A., de Lamballerie, X., Guedj, J., Taburet, A.-M., & Mentré, F. (2016). Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. *Clinical Pharmacokinetics*, 55(8), 907–923. <https://doi.org/10.1007/s40262-015-0364-1>

Montané, E., & Santesmases, J. (2020). Reacciones adversas a medicamentos. *Medicina Clínica*, 154(5), 178–184. <https://doi.org/10.1016/j.medcli.2019.08.007>

Mousavizadeh, L., & Ghasemi, S. (2021). Genotype and phenotype of COVID-19: Their roles in pathogenesis. *Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi*, 54(2), 159–163. <https://doi.org/10.1016/j.jmii.2020.03.022>

Podder, V., & Sadiq, N. M. (2021). Levofloxacin. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK545180/>

Prabhakar, H., Kapoor, I., & Mahajan, C. (Eds.). (2020). *Clinical Synopsis of COVID-19: Evolving and Challenging*. Springer Singapore. <https://doi.org/10.1007/978-981-15-8681-1>

Rahayu, L. A. D., Admiyanti, J. C., Khalda, Y. I., Ahda, F. R., Agistany, N. F. F., Setiawati, S., Shofiyanti, N. I., & Warnaini, C. (2021). Hipertensi, Diabetes Mellitus, dan Obesitas Sebagai Faktor Komorbiditas Utama Terhadap Mortalitas Pasien COVID-19: Sebuah Studi Literatur. *JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia*, 9(1), 90–97. <https://doi.org/10.53366/jimki.v9i1.342>

Rumah Sakit Umum Daerah Ulin. (2022). Retrieved January 3, 2022, from <http://rsulin.kalselprov.go.id/profil.html>

Sifareina, S., Alifiar, I., & Priatna, M. (2021). Studi Farmakovigilans Pada Pasien COVID-19. *Pharmacoscript*, 4(2), 194–208. <https://doi.org/10.36423/pharmacoscript.v4i2.729>

Tomazini, B. M., Maia, I. S., Cavalcanti, A. B., Berwanger, O., Rosa, R. G., Veiga, V. C., Avezum, A., Lopes, R. D., Bueno, F. R., Silva, M. V. A. O.,

- Baldassare, F. P., Costa, E. L. V., Moura, R. A. B., Honorato, M. O., Costa, A. N., Damiani, L. P., Lisboa, T., Kawano-Dourado, L., Zampieri, F. G., ... COALITION COVID-19 Brazil III Investigators. (2020). Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*, 324(13), 1307. <https://doi.org/10.1001/jama.2020.17021>
- Utama, A., & Intan, G. (2021). *Lonjakan Virus Corona Varian Delta di Indonesia*. VOA Indonesia. Retrieved November 3, 2021, from <https://www.voaindonesia.com/a/lonjakan-virus-corona-varian-delta-di-indonesia/5934021.html>
- Wu, T.-Y., Jen, M.-H., Bottle, A., Molokhia, M., Aylin, P., Bell, D., & Majeed, A. (2010). Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. *Journal of the Royal Society of Medicine*, 103(6), 239–250. <https://doi.org/10.1258/jrsm.2010.100113>
- Yasir, M., Goyal, A., Bansal, P., & Sonthalia, S. (2021). Corticosteroid Adverse Effects. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK531462/>